AU2014292371B2 - Fusokines involving cytokines with strongly reduced receptor binding affinities - Google Patents

Fusokines involving cytokines with strongly reduced receptor binding affinities Download PDF

Info

Publication number
AU2014292371B2
AU2014292371B2 AU2014292371A AU2014292371A AU2014292371B2 AU 2014292371 B2 AU2014292371 B2 AU 2014292371B2 AU 2014292371 A AU2014292371 A AU 2014292371A AU 2014292371 A AU2014292371 A AU 2014292371A AU 2014292371 B2 AU2014292371 B2 AU 2014292371B2
Authority
AU
Australia
Prior art keywords
pct
artificial sequence
fusion protein
primer
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014292371A
Other languages
English (en)
Other versions
AU2014292371A1 (en
Inventor
Yann BORDAT
Jennyfer BULTINCK
Sarah Gerlo
Franciane PAUL
Jan Tavernier
Gilles Uze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier filed Critical Universiteit Gent
Publication of AU2014292371A1 publication Critical patent/AU2014292371A1/en
Application granted granted Critical
Publication of AU2014292371B2 publication Critical patent/AU2014292371B2/en
Priority to AU2018203868A priority Critical patent/AU2018203868B2/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITEIT GENT, VIB VZW, UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Amend patent request/document other than specification (104) Assignors: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, UNIVERSITEIT GENT, VIB VZW
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2014292371A 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities Active AU2014292371B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018203868A AU2018203868B2 (en) 2013-07-18 2018-06-01 Fusokines involving cytokines with strongly reduced receptor binding affinities

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306034.3 2013-07-18
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203868A Division AU2018203868B2 (en) 2013-07-18 2018-06-01 Fusokines involving cytokines with strongly reduced receptor binding affinities

Publications (2)

Publication Number Publication Date
AU2014292371A1 AU2014292371A1 (en) 2016-02-04
AU2014292371B2 true AU2014292371B2 (en) 2018-03-29

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014292371A Active AU2014292371B2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities
AU2018203868A Active AU2018203868B2 (en) 2013-07-18 2018-06-01 Fusokines involving cytokines with strongly reduced receptor binding affinities

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018203868A Active AU2018203868B2 (en) 2013-07-18 2018-06-01 Fusokines involving cytokines with strongly reduced receptor binding affinities

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3299466B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN110835376B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2657060T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG11201600163VA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
WO2019032661A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3115318B2 (ja) * 1989-08-22 2000-12-04 イミュネックス・コーポレーション Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
EP2173377B1 (en) 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
CA2779512C (en) * 2009-11-02 2017-01-17 Leonard H. Rome Vault complexes for cytokine delivery
EP2515916B1 (en) * 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
UA125637C2 (uk) * 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Also Published As

Publication number Publication date
US12410222B2 (en) 2025-09-09
ES2757501T3 (es) 2020-04-29
BR112016001036B1 (pt) 2023-02-23
SG11201600163VA (en) 2016-02-26
CA2917937C (en) 2022-11-01
JP2020002155A (ja) 2020-01-09
CN105705641B (zh) 2021-07-13
JP2016525516A (ja) 2016-08-25
WO2015007536A2 (en) 2015-01-22
AU2018203868A1 (en) 2018-06-21
EP3022305A2 (en) 2016-05-25
BR112016001036A2 (pt) 2017-10-24
WO2015007536A3 (en) 2015-03-19
ES2657060T3 (es) 2018-03-01
CN105705641A (zh) 2016-06-22
US20190010199A1 (en) 2019-01-10
IL243451B (en) 2019-10-31
CN110835376B (zh) 2023-08-04
EP3299466B1 (en) 2019-09-11
MX375441B (es) 2025-03-06
DK3299466T3 (da) 2019-11-18
US20180155404A1 (en) 2018-06-07
CA2917937A1 (en) 2015-01-22
KR102322510B1 (ko) 2021-11-08
AU2018203868B2 (en) 2019-12-05
KR20160108291A (ko) 2016-09-19
US11358997B2 (en) 2022-06-14
JP6580037B2 (ja) 2019-09-25
EP3299466A1 (en) 2018-03-28
MX2016000611A (es) 2016-09-29
HK1252831A1 (en) 2019-06-06
IL243451A0 (en) 2016-03-31
CN110835376A (zh) 2020-02-25
AU2014292371A1 (en) 2016-02-04
EP3022305B1 (en) 2017-11-01
JP6853317B2 (ja) 2021-03-31
US20230054612A1 (en) 2023-02-23
SG10201808738WA (en) 2018-11-29
US10640542B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
US12410222B2 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
AU2015301936B2 (en) Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
EP3172227B9 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20180100237A (ko) 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
AU2002324249B2 (en) Interleukin-18 mutants, their production and use
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
HK1252831B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069A1 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
JP3689111B2 (ja) インターロイキン１５

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UNIVERSITEIT GENT

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTP

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: VIB VZW

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: UNIVERSITE DE MONTPELLIER

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

FGA Letters patent sealed or granted (standard patent)